Continuous intrathecal baclofen infusion via a subcutaneously implanted programmable pump has been used in the treatment of severe spasticity. Improvement classically concerns the neurological (hypertonia, spasms, hyperre¯exia), urological (bladder function) and other clinically relevant outcomes, such as functional status of daily living. This short note reports on another eect of intrathecal baclofen on vasomotor disorders and cyanosis in the lower limbs, described in a patient with spastic paraplegia.
Introduction
Baclofen (b-4-chlorophenyl g-amino-butyric acid) is a derivative of the inhibitory neurotransmitter g-aminobutyric acid (GABA). Its mode of action is not fully understood. It interferes with the release of excitatory neurotransmitters and inhibits monosynaptic and polysynaptic transmission at the spinal level. It may also act at supraspinal sites producing CNS depression. Baclofen is used in the treatment of spasticity, decreases muscle spasms, pain and urinary-tract disorders especially in case of spinal cord lesions. 1, 2 In patients with severe spasticity, baclofen can be given intrathecally when medical treatment, including oral baclofen administration, diazepam or sodium dantrolene has failed or adverse eects limit increases in dosage. 3 Here we report the improvement of vasomotor disorders with intrathecal administration of baclofen, in a patient with a severe disabilitating spasticity secondary to spinal cord lesion.
History
The patient was a 39-year-old male who had a car accident in 1972. He initially was comatose for 5 days, and had a compressive fracture of the 3rd and 4th thoracic vertebrae with complete paraplegia. The vertebral fractures were treated by an orthopaedic treatment. No neurological recovery had occurred. After rehabilitation, the patient was independent for daily life activities in a wheelchair. Fifteen years later, he developed increasing spasticity with severe muscular hypertonia, frequent spontaneous spasms and increasing re¯exes. He also showed an urge incontinence consecutive to a severe hyperactive bladder with frequent unvoluntary contractions.
Examination
Neurological examination revealed a complete spastic paraplegia below the T4 level and a severe spasticity with muscular hypertonia, spasms and hyperre¯exia (Table 1) . Urodynamic evaluation showed a hyperactivity with detrusor hyper-re¯exia and a detrusor sphincter dyssynergia (Table 1) . Radiographic visualization of the bladder during storage and voiding showed a spastic bladder of small size with trabeculations and diverticuli. As veri®ed on MRI, this clinical worsening did not result form a post-traumatic centromedullary cavity.
Moreover, the patient showed vasomotor disorders in his two lower limbs, with marked cyanosis and reduction of the super®cial temperature, although the dierent arterial pulses were present at examination. Thermography examination revealed an important decrease of the super®cial temperature in his two lower limbs (Figure 1a ).
Treatment
The patient's spasticity was refractory to orally administered baclofen. Spasticity was reduced by a *Correspondence: G Rode MD, PhD, Service de ReÂ eÂ ducation Neurologique, HoÃ pital Henry Gabrielle, Hospices Civils de Lyon, route de Vourles, B.P. 57, 69565 Saint-Genis Laval Cedex, France trial bolus of 100 mg of intrathecal baclofen. Criteria for inclusion and exclusion to intrathecal baclofen therapy by an implanted pump, proposed by Penn were respected: age was between 18 and 65 years; severe chronic spasticity was due to a spinal cord trauma; the patient had adequate CSF¯ow as determined by myelogram; prior to implantation of a pump, the patient had responded to a single dose of 100 mg of intrathecal baclofen and the patient had voluntarily signed the informed consent form after its contents had been fully explained. 4 A programmable pump (SynchroMed TM , Medtronic, Minneapolis, USA) was implanted in the abdominal wall and connected to a lumbar subarachnoid catheter introduced under uoroscopic control in October 1992. The eective daily dose was 180 mg.
After implantation, an improvement of spasticity was noted: reduction of increase in muscle tone and normal re¯exes. Bladder capacity was increasing as proved by cystography (200 cc) and urodynamic evaluation showed a reduction of the detrusor hyperre¯exia (Table 1) . Moreover, a regression of vasomotor disorders was dramatically observed through intrathecal baclofen. The cyanosis had disappeared and the thermography examination showed an increase of the super®cial temperature (+78C) and no dierence between the two limbs ( Figure 1b) . This improvement was long-lasting.
In this case, intrathecal baclofen improved dierent symptoms of spasticity: muscular hypertonia, muscle spasms, hyper-re¯exia and urinary-tract disorders. These positive eects were comparable to those previously reported. 7 ± 10 In this case, a supplementary eect of intrathecal baclofen on vasomotor disorders and cyanosis in the two lower limbs was reported. Two explanations may be proposed to explain this eect: ®rstly, the regression of vasomotor disorders and cyanosis may be due to the muscle tone reduction which disturbed the blood circulation in the lower limbs. Secondly, intrathecal baclofen may have a direct vasomotor eect. Ecacy measurements consisted to evaluate rigidity, spasms and re¯exes using three dierent scales: (i) The ®ve-point Ashworth scale 5 for measuring muscle tone (1=No increase in tone; 2=Slight increase in tone, giving a`catch' when aected part is moved in¯exion or extension; 3=More marked increase in tone, but aected part easily¯exed; 4=Considerable increase in tone; passive movement dicult; 5=Aected part rigid in¯exion or extension), (ii) A ®ve-point scale for spasms (0=No spasms; 1=Mild spasms induced by stimulation; 2=Infrequent full spasms occurring less than once per hour; 3=Spasms occurring more than once per hour; 4=Spasms occurring more than ten times per hour) and (iii) A ®ve-point scale for re¯exes (0=Absent; 1=Hypore¯exive; 2=Normore¯exive; 3=Mild hyperreflexive; 4=3 ± 4 beats clonus; 5=Clonus). Urinary tract disorders were assessed by urodynamic exploration and cystography 6 Figure 1 Thermography examination of the lower limbs before (a) and after intrathecal baclofen (180 mg/day) (b) in a case of spasticity paraplegia. Before treatment, the super®cial temperature was included between 22.5 and 238C. After treatment, the super®cial temperature was increased and between 29 and 308C. Examination did not show dierence between the two limbs A complete peripheral vasodilatation has already been described in two cases following an overdose of baclofen. 11, 12 The two patients were totally comatose and¯accid, and showed also a collapse and a bradycardia. In these two cases, the overdose of baclofen was respectively 500 and 900 mg of baclofen per os. The clinical and pharmacological status of our patient was dierent. The vasomotor eect was induced by high level of intrathecal baclofen without peripheral eect. This eect might be consecutive to a selection action of baclofen on autonomic innervation with the spinal cord.
Baclofen interferes with the release of excitatory neurotransmitters and inhibits monosynaptic and polysynaptic transmissions at the spinal level. Within the spinal cord, the receptors for baclofen, gammaaminobutyric acid (GABA)B receptors, have been shown to have greatest density in the substantia gelatinosa (lamina II) of the spinal cord in both rats and humans. 13, 14 The substantia gelatinosa is the central site of termination of most primary aerent ®bres excited by painful stimuli and contains many interneurones which form a network that plays a role in modulating the primary aerent signals. 15, 16 The exact role of the substantia gelatinosa remains to be determined. The vasomotor eect induced by intrathecal baclofen may be linked to this neuronal circuitry of the substania gelatinosa. In an animal, experimental studies moreover showed that baclofen has a powerful sympatho-inhibitory eect on sympathetic preganglionic neurones and that the baclofen-sensitive receptors in the spinal cord could be involved in regulating sympathetic output in pathways to the vessels and/or to the heart. 17, 18 These ®ndings support the clinical eect observed in this human pathological case. Finally, it is interesting to note that this result, with no equivalent found in the literature, was observed 15 years after paraplegia and in long-standing vasomotor disorders which were initially considered permanent and probably irreversible.
